Veterinary

Gallant Reports Positive Pilot Data for Feline Osteoarthritis Stem Cell Therapy; Receives FDA Eligibility for Expanded Conditional Approval Pathway

Gallant said its pilot study found that intravenous stem cell therapy significantly improved pain and quality of life in cats with osteoarthritis versus placebo, supporting a faster regulatory route as the company...

Orthopedic, Regulatory | April 17, 2026

Interview: Veterinary Stem Cells – Gallant’s Quest for the First FDA-Approved MSC Therapy

Gallant is betting the future of veterinary regenerative medicine lies in scalable, well-characterized cell therapies. By sourcing mesenchymal stem cells from uterine tissue collected during routine spays, it has built an off-the-shelf...

Immunology, Manufacturing | April 17, 2026

Gallant’s Veterinary Stem Cell Therapy Nabs Key Safety Requirement from FDA for Cats with Severe Oral Disease

Gallant is inching closer to making veterinary history, potentially launching the first off-the-shelf stem cell product in the field next year.

Veterinary | November 17, 2025